Terms: = Endocrine gland cancer AND SETD2, ENSG00000181555, 29072
17 results:
1. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
[No Abstract] [Full Text] [Related]
2. setd2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract] [Full Text] [Related]
3. Dysregulation of miR-551b-5p and
Dong A; Gao M; Zheng X; Ruan X
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1400-1409. PubMed ID: 37073141
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Genetics of Diffuse Sclerosing Papillary Thyroid cancer.
Alswailem M; Alghamdi B; Alotaibi A; Aljomiah A; Al-Hindi H; Murugan AK; Abouelhoda M; Shi Y; Alzahrani AS
J Clin Endocrinol Metab; 2023 Aug; 108(9):e704-e711. PubMed ID: 36995892
[TBL] [Abstract] [Full Text] [Related]
5. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract] [Full Text] [Related]
6. Tumor Cell-Intrinsic setd2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.
Niu N; Shen X; Zhang L; Chen Y; Lu P; Yang W; Liu M; Shi J; Xu D; Tang Y; Yang X; Weng Y; Zhao X; Wu LM; Sun Y; Xue J
Adv Sci (Weinh); 2023 Jan; 10(2):e2202937. PubMed ID: 36453584
[TBL] [Abstract] [Full Text] [Related]
7. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract] [Full Text] [Related]
8. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in setd2-deficient pancreatic cancer.
Shen X; Chen Y; Liu M; Shi J; Tang Y; Yang X; Xu D; Yao H; Lu P; Sun Y; Xue J; Niu N
Biochem Biophys Res Commun; 2022 Jul; 615():9-16. PubMed ID: 35679751
[TBL] [Abstract] [Full Text] [Related]
9. Molecular analysis of adenocarcinomas of the rete testis demonstrates frequent alterations in genes involved in cell cycle regulation.
Acosta AM; Al-Obaidy KI; Sholl LM; Ulbright TM; Idrees MT
Histopathology; 2022 Jul; 81(1):77-83. PubMed ID: 35395117
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary gland: A Case Report.
Hong CS; Elsamadicy AA; Fisayo A; Inzucchi SE; Gopal PP; Vining EM; Erson-Omay EZ; Bulent Omay S
Front Endocrinol (Lausanne); 2021; 12():762095. PubMed ID: 34925233
[TBL] [Abstract] [Full Text] [Related]
12. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
13. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract] [Full Text] [Related]
14. Expression and prognostic value of NSD1 and setd2 in pancreatic ductal adenocarcinoma and its precursor lesions.
Ettel M; Zhao L; Schechter S; Shi J
Pathology; 2019 Jun; 51(4):392-398. PubMed ID: 31060750
[TBL] [Abstract] [Full Text] [Related]
15. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract] [Full Text] [Related]
16. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract] [Full Text] [Related]
17. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Varela I; Tarpey P; Raine K; Huang D; Ong CK; Stephens P; Davies H; Jones D; Lin ML; Teague J; Bignell G; Butler A; Cho J; Dalgliesh GL; Galappaththige D; Greenman C; Hardy C; Jia M; Latimer C; Lau KW; Marshall J; McLaren S; Menzies A; Mudie L; Stebbings L; Largaespada DA; Wessels LF; Richard S; Kahnoski RJ; Anema J; Tuveson DA; Perez-Mancera PA; Mustonen V; Fischer A; Adams DJ; Rust A; Chan-on W; Subimerb C; Dykema K; Furge K; Campbell PJ; Teh BT; Stratton MR; Futreal PA
Nature; 2011 Jan; 469(7331):539-42. PubMed ID: 21248752
[TBL] [Abstract] [Full Text] [Related]
